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Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for
inducing clinical regressions by targeting tumor-associated antigens (TAA). To expand the
TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we performed tandem mass
spectrometry analysis of HLA class I-bound peptides from 35 PDAC patient tumors. This
identified a shared HLA-A*0101 restricted peptide derived from co-transcriptional activator
Vestigial-like 1 (VGLL1) as a putative TAA demonstrating overexpression in multiple tumor
types and low or absent expression in essential normal tissues. Here we show that VGLL1-
specific CTLs expanded from the blood of a PDAC patient could recognize and kill in an
antigen-specific manner a majority of HLA-A*0101 allogeneic tumor cell lines derived not only
from PDAC, but also bladder, ovarian, gastric, lung, and basal-like breast cancers. Gene
expression profiling reveals VGLL1 as a member of a unique group of cancer-placenta anti-
gens (CPA) that may constitute immunotherapeutic targets for patients with multiple
cancer types.
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Pancreatic ductal adenocarcinoma (PDAC), the mostaggressive form of pancreatic cancer, remains notorious forits poor prognosis and high mortality rate, with its overall
5-year survival rate of 8% being amongst the lowest of all cancer
types1,2. Early detection is unusual, with 85% of patients pre-
senting with locally advanced or metastatic disease3. Progress
toward effective treatment has been slow and the incidence of
PDAC-related deaths has continued to rise4,5. Despite some
encouraging recent improvements in survival achieved through
optimizing the sequencing of surgery and chemotherapy treat-
ment regimens, developing new and effective therapeutic options
remains a dire need for advanced-stage PDAC patients6.
Cytotoxic T lymphocyte (CTL)-based immunotherapies have
been successful at inducing objective clinical responses in a
variety of cancer types7. Checkpoint inhibitor (CPI) therapies that
act through non-specific activation of T lymphocytes have made a
significant positive impact on long-term patient survival8. How-
ever, the benefits of CPI have mainly been limited to highly
mutated tumor types like melanoma and lung adenocarcinoma
that can express a large array of potential neo-antigen peptides in
the context of surface HLA molecules5,9. Tumor-infiltrating
lymphocyte (TIL) therapy, in which individual cancer patients are
re-infused with T cells expanded from their own tumors, has also
shown great promise for inducing the regression of bulky
tumors.10,11 TILs are polyclonal and can recognize both patient-
specific neo-antigens as well as shared tumor-associated antigens
(TAA) such as melanocyte differentiation antigens (MDA) or
cancer-testis antigens (CTA)12–14. Targeting of individual
validated HLA class I-restricted TAAs through infusion of
antigen-specific endogenous T cells (ETC therapy) or genetically
engineered TCR-T cells has also proven successful at inducing
clinical responses in patients with melanoma and other solid
cancers15–19.
CPI- and CTL-based immunotherapies have unfortunately not
shown the same beneficial impact in treating PDAC patients20,21.
This lack of success has been attributed to the highly immune-
suppressive tumor microenvironment (TME) of PDAC, in addi-
tion to the relatively low mutational burden that contributes to a
dearth of neo-antigen targets22–25. A number of potentially tar-
getable HLA class I-restricted peptide antigens have been identi-
fied in PDAC, most notably those derived from carcinoembryonic
antigen-related cell adhesion molecule (CEACAM), mucin 16
(MUC16), mesothelin (MSLN), and mutated KRAS, among oth-
ers26–30. Although promising, therapies targeting non-mutated
TAAs have faced inherent limitations, including the induction of
toxicities in non-tumor tissues, low prevalence of target antigen
expression, or inability to break self-tolerance mechanisms that
often hinders the generation of high-affinity CTLs20,31,32. With
limited exceptions, clinical trials targeting these antigens have
yielded disappointing results, underscoring the need to identify
safe, immunogenic targets that demonstrate higher prevalence in
PDAC patients.
In order to expand the targetable TAA landscape of PDAC, we
performed tandem mass spectrometry (MS) analysis on HLA
class I-bound peptide antigens isolated from tumor specimens
derived from 35 PDAC patients. We report here the discovery of
a shared, HLA-A*0101-restricted peptide derived from the co-
transcriptional activator Vestigial-like 1 (VGLL1) that was
expressed and presented in multiple patients. VGLL1 peptide-
specific CTLs isolated and expanded from PBMCs (peripheral
blood mononuclear cells) of a PDAC patient robustly killed
autologous tumor cells, in addition to recognizing a panel of
allogeneic HLA-A*0101-positive PDAC, ovarian, gastric, blad-
der, lung, and basal-like breast cancer cell lines. With the
exception of a mammary cell line, VGLL1 CTLs did not recog-
nize most HLA-A*0101-expressing matched normal primary
cells. Patient infusion of autologous VGLL1 CTLs resulted in no
autoimmune toxicities but also failed to induce a clinical
response, likely due to VGLL1 antigen loss by the metastatic
tumor33. Comparative gene expression profiling revealed that
VGLL1 is a member of a unique group of cancer-placenta
antigens (CPA) that demonstrate high expression in placenta,
low to absent expression in essential normal tissues, and over-
expression in several different cancers. Collectively, our results
show that VGLL1 is an immunogenic TAA target with strong
potential for enabling CTL-mediated therapies for PDAC and
multiple other cancer types.
Results
Immunopeptidome analysis of PDAC identifies tumor-
associated peptides. To identify peptide targets for CTL-based
immunotherapy of PDAC, we analyzed 39 tumor specimens
derived from 35 PDAC patients treated at M.D. Anderson Cancer
Center. This included 34 freshly-excised surgical specimens (20
metastatic and 14 primary tumors), in addition to 3 patient-
derived xenografts (PDX) and 2 organoid cell lines derived from
metastases. Tumor cells were lysed and subjected to total HLA
class I immunoprecipitation and acid elution, followed by tandem
mass spectrometry (MS) to analyze the HLA-bound peptides.
Eluted peptide fragmentation spectra were searched against the
SwissProt database (updated 9/2018) to identify matches encoded
within the human proteome. Individual peptide matches were
assessed using several orthogonal parameters, including Mascot
Ion score, MS1 mass differential (delta mass), and predicted
binding to the patient’s HLA allotypes as determined by high-
resolution genetic sequencing34,35. Further validation and poten-
tial suitability as therapeutic TAA targets were determined by
evaluating all peptide-encoding genes for (1) patient tumor tissue
transcript expression as determined by RNAseq, (2) normal tissue
transcript expression (GTex Portal database), and (3) overall
expression in tumor tissues (TCGA database) (Fig. 1a) (http://
www.gtexportal.org/home/, http://cancergenome.nih.gov/).
The amount of immunoprecipitated HLA class I correlated
with the size of the fresh tumor specimens analyzed (R2= 0.79),
with the exception of 8 tumors (21.6%) that showed relatively low
HLA class I expression as assessed by western blot analysis.
Overall, the 39 tumor specimens analyzed yielded a total of
23,245 unique, high-confidence peptide identities, of which 7966
peptides (34.3%) were 8- to 13-mer peptides predicted to bind to
one or more patient HLA class I allotypes. Fresh tumor specimens
yielded a highly variable number of peptides, ranging from 238 to
1657 (mean= 542). For three patients, PDX derivation resulted
in larger tumor specimens, yielding an increased number of
eluted peptides. One of the two patient-derived organoid cell lines
(MP015) yielded the highest number of eluted peptides overall
(n= 1903), underscoring the quantitative advantage provided by
expanding tumor specimens in vitro prior to MS analysis
(Supplementary Table 1).
Expression profiling identified VGLL1 as a putative pancreatic
cancer TAA. To evaluate if any of the eluted peptides constituted
potentially therapeutic CTL targets, peptide-encoding genes were
individually assessed for normal tissue transcript expression with
reference to the GTex Portal database containing RNAseq data
derived from 53 different human tissues. Normal tissues
(excluding testis) were categorized into four groups that reflected
the potential toxicities expected from off-target killing activity by
antigen-specific CTLs (Supplementary Table 2). Peptide-encoding
genes were then screened using four corresponding expression
filters of increasing stringency in order to eliminate candidate
TAAs most likely to elicit autoimmune toxicity in the context of
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CTL therapy (Fig. 1b). Thus, while TAA transcript expression up
to 30 TPM maximum was allowed in non-essential tissues (such
as prostate, breast, and adipose tissues), a maximum expression
threshold of 1 TPM was imposed for highly essential tissues such
as heart and brain, for which CTL recognition can be lethal.36,37.
Using these stringent criteria, 12 TAA peptides were deemed
safest to target, the genes encoding these peptides being MUC16
(encoding 5 unique peptides), MUC19, ZNF717, EIF5AL1,
RGPD1, SLC30A8, MIA2, and VGLL1 (each encoding 1 unique
peptide). Peptides encoded by TAAs MSLN and IDO1 were also
detected, but were excluded in the screening due to elevated RNA
transcript expression in normal lung tissue (88 TPM and 16
TPM, respectively, Fig. 1b). Amongst the TAAs deemed safest to
target, only 2 peptides (derived from MIA2 and VGLL1) were
found to be presented by tumors of more than one PDAC patient
(Supplementary Table 1). A number of these same peptides,
including those derived from MUC16 and IDO1, have also been
reported to be expressed in the immunopeptidome of ovarian
cancer specimens38.
The 10-mer peptide LSELETPGKY, uniquely encoded by
VGLL1, was eluted from both PDAC patient-derived organoid
cell lines MP015-Org and MP081-Org (Supplementary Data 1
and 2). This peptide was predicted to bind with high affinity to
HLA-A*0101 (51 nM), and RNAseq analysis confirmed high
VGLL1 transcript expression in both organoid lines (Table 1).
Peptide identity was confirmed by targeted LC-MS, in which a
synthetic peptide was analyzed as part of a mixture with organoid
tumor-associated peptides. As shown in Fig. 1c, the synthetic
isotope-labeled peptide LSELETPGKY generated highly similar
fragmentation spectra to the native VGLL1 peptide detected from
PDAC organoid lines MP015-Org and MP081-Org, and was co-
eluted at identical LC-MS retention times. Targeted-MS analysis
on two additional HLA-A*0101-expressing cell lines (PANC10.05
and BXPC3) demonstrated that the same peptide could also be
detected on PANC10.05, suggesting that LSELETPGKY might
constitute a widely shared TAA (Supplementary Fig. 1).
VGLL1 is expressed by multiple cancers and is associated with
poor survival. VGLL1, previously known as TONDU, was first
identified as the human homolog of the Drosophila Vestigial (Vg)
protein, a key regulator of wing development39,40. Since VGLL1 is
a transcriptional co-activator that binds to the TEA domain
(TEAD) family of transcription factors implicated in cancer
development, we examined VGLL1 transcript expression in the 33
cancer types listed in TCGA. As shown in Fig. 2a, in comparison
to most normal tissues VGLL1 is overexpressed in several dif-
ferent cancers, including PDAC, bladder, ovarian, breast, lung,
and stomach cancer. Interestingly, VGLL1 appears to be pre-
ferentially expressed in basal-like breast cancers while demon-
strating a relatively low prevalence in other breast cancer subtypes

































































































































































































200 300 400 500 600 700 800 900 1000
200 300 400 500 600 700 800 900 1000





















































































Fig. 1 Immunopeptidome analysis reveals a VGLL1-derived peptide expressed by two PDAC patient-derived organoid lines. a Experimental strategy to
identify PDAC tumor-specific, HLA class I-bound peptides from 39 tumor specimens derived from 35 M.D. Anderson PDAC patients. b Bioinformatics
screening strategy to identify potentially targetable TAAs from amongst the eluted PDAC-associated peptides. Peptide-encoding genes were assessed for
PDAC tumor RNAseq expression compared with transcript expression in 53 GTex Portal normal tissues. Excluding testis, normal tissues were separated
into four categories (non-essential, caution, hazard, and danger tissues) that reflected the potential toxicities expected from off-tumor killing activity
against different tissues (listed in Table S2). All peptide-encoding genes were filtered successively using four corresponding expression thresholds of
increasing stringency (30, 10, 3, and 1 TPM, indicated by green dotted lines) to eliminate candidate TAAs most likely to elicit autoimmune toxicity in the
context of CTL therapy (red dotted lines). Screening of high-confidence peptides isolated from tumor organoid cell lines of PDAC patients MP015 and
MP081 is depicted, showing that few eluted peptides met these stringent criteria. c Mass spectra of an HLA-A*0101-restricted VGLL1-derived peptide
isolated from two different PDAC organoid cell lines, MP015 and MP081 (top 2 panels). The patient-derived peptides co-eluted with and matched the MS
fragmentation spectra of the synthetic isotope-labeled VGLL1 peptide LSELETPGKY (containing a 13C/15N-labeled lysine residue), with the labeled y+
fragment ion series (shown in blue) demonstrating an expected shift of 8 atomic mass units, unlike the b+ fragment ions (bottom panel). IP
immunoprecipitation, TPM transcripts per million, TAA tumor-associated antigen.
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(Supplementary Fig. 2). A similar profile was confirmed by gene
expression analysis of tumor cell lines listed in the Cancer Cell
Line Encyclopedia (CCLE, Supplementary Fig. 3). According to
the GTex RNAseq database, the highest median VGLL1 transcript
expression was found in four non-essential tissues: bladder (15.3
TPM), salivary gland (3.9 TPM), breast (1.3 TPM), and pituitary
gland (1.0 TPM). The highest level of VGLL1 transcript expres-
sion in essential tissues was in normal lung (1.0 TPM), esophagus
(0.73 TPM), and kidney (0.34 TPM), while VGLL1 expression in
heart and brain tissues was virtually undetectable (Fig. 2a). Col-
lectively, this data suggested that VGLL1 may constitute a safe,
targetable TAA for multiple cancer types.
We next assessed if tumor VGLL1 transcript expression was
associated with cancer patient survival. As shown in Fig. 2b,
TCGA PDAC patient survival (n= 179) was found to be
inversely correlated with VGLL1 expression: patients with high
expression had a significantly shorter overall median survival
compared to patients with low or absent expression (16 months
vs. 37 months, p= 0.001). This was confirmed in an independent
cohort of 42 M.D. Anderson PDAC patients for whom PDX
tissues could be derived: patients showing an overall survival of
less 18 months demonstrated a significantly higher mean PDX
VGLL1 expression compared to patients that survived longer than
36 months (48.5 TPM vs. 4.4 TPM, p= 0.003, Fig. 2c). It is worth
noting that VGLL1 transcript expression was found to be
considerably higher in PDAC tumor cell lines and PDX tissues
compared with surgically resected PDAC tumors, likely due to the
high stromal content of many PDAC tumors in situ (Fig. 2a, c,
Table 1 VGLL1-derived peptide eluted from two HLA-A*0101+ PDAC patient tumor organoids.
Patient
identifier




MP015 LSELETPGKY VGLL1 1 77.53 51
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Fig. 2 VGLL1 is overexpressed in multiple tumor types and is associated with poor pancreatic patient survival. a VGLL1 transcript expression in normal
tissues (colored dots, GTex Portal database) and human cancers (black dots, TCGA database), as determined by RNAseq analyses. Each dot represents
one normal donor or patient tumor sample. Colors correspond to the four normal tissue categories defined in Fig. 1: Green, non-essential tissues; yellow,
caution tissues; orange, hazard tissues; red, danger tissues. While >95% of normal GTex caution, hazard, and danger tissue samples fell below 3 transcripts
per million (TPM, dotted line), significant numbers of TCGA cancer patients demonstrated VGLL1 transcript expression above this threshold (red box).
b Kaplan–Meier curves showing TCGA PDAC patient overall survival (OS) stratified by tumor VGLL1 transcript expression (n= 178). P-values indicate log-
rank significance test results comparing the OS of three groups of VGLL1-expressing patients to those patients with low or absent VGLL1 expression using
Gehan–Breslow–Wilcoxon test. c Patient-derived xenografts (PDX) from an independent cohort of MD Anderson metastatic PDAC patient tumors (n=
42) underwent RNAseq analysis after being grown in immunodeficient mice. Graph shows PDX specimens stratified into three groups corresponding to OS
time and corresponding VGLL1 transcript expression. Data are presented as mean values+/− standard deviation. P-values indicate log-rank significance
test results comparing each group using an ANOVA test. Adjustments were made for multiple comparisons.
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Table 1). Highly elevated VGLL1 expression was also associated
with shorter overall survival time in breast cancer (p= 0.037) and
stomach cancer (p= 0.047), but showed no association with
survival in ovarian cancer (Supplementary Fig. 4)41. Interestingly,
low or absent VGLL1 expression was associated with shorter
survival time in bladder cancer (p= 0.036). One potential
explanation is that loss of a normal bladder tissue antigen like
VGLL1 may indicate tumor dedifferentiation, which has been
associated with poorer prognosis in bladder cancer and many
other tumor types42.
VGLL1 is a cancer-placenta antigen (CPA) with therapeutic
potential. VGLL1 had been previously identified as having a
regulatory role during early events in human placental develop-
ment, and is a specific marker of proliferative and invasive
cytotrophoblast cells43. In accordance with this, RNAseq gene
expression data from seven human placenta samples showed that
VGLL1 demonstrated the highest expression in this tissue by a
large margin (mean= 302.7 TPM), nearly 20-fold higher than its
expression in normal bladder (Fig. 3a). This led us to explore the
notion that cancer-placenta antigens (CPA) may constitute a
distinct category of targetable TAAs analogous to cancer-testis
antigens (CTAs), which have been successfully targeted with
CTL-based therapies. To identify other CPAs with similar
expression profiles to VGLL1, we searched the GTex, TCGA, and
other RNAseq databases for genes that demonstrated the
following attributes: (1) highest normal tissue expression in pla-
centa; (2) low to absent expression in other normal tissues; and
(3) elevated expression in pancreatic, breast, bladder, and/or
ovarian cancer. This search yielded nine additional genes,
including placenta-specific 1 (PLAC1), previously identified as a
target of humoral antitumor immunity in cancer patients44.
Interestingly, Chorionic Gonadotropin (CG) Beta subunits 3 and
5 (CGB3/CGB5), components of the CG hormone complex pro-
duced by placental trophoblasts during pregnancy, were also
identified as potential CPAs due to their overexpression in a
subset of pancreatic, testicular, uterine, and bladder cancers
(Fig. 3b). The other 6 putative CPAs demonstrated diverse
expression profiles, ranging from those found only in a restricted
set of cancer types (IGF2BP3, ADAM12), to those overexpressed
in most cancer types but also demonstrating elevated expression
in normal female reproductive tissues (CAPN6, MMP11) (Fig. 3,
Supplementary Figs. 5–15, Supplementary Tables 3–6). Although
we did not detect peptides derived from these genes in this set of
PDAC specimens, epitopes from several of these putative CPAs
have been identified in multiple tumor types and are listed in the
Immune Epitope Database (IEDB)44.
VGLL1-specific CTLs were expanded from PDAC patient
MP015. Patient MP015 was first diagnosed with primary PDAC
in December 2011. As previously reported, two years following
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Fig. 3 VGLL1 is a cancer-placenta antigen (CPA) demonstrating high expression in normal placenta and tumors. Gene expression profiling uncovered
nine additional putative CPAs with similar expression profiles to VGLL1. a Heat map depicting the mean transcript expression of different CPAs in normal
placenta (top), GTex normal tissues, and transformed lymphocytes and fibroblasts (bottom). Tissues are listed in order of highest to lowest VGLL1
expression, as determined by RNAseq analysis. b Heat maps displaying the mean CPA transcript expression (left) and frequency (right) of CPA-positive
tumor specimens in 34 different TCGA cancer types as determined by RNAseq. CPA-positive specimens were defined as having tumor CPA transcript
expression >5 TPM. Tumor tissues are listed in order of highest to lowest VGLL1 prevalence.
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wedge resection of a left lung lesion was performed in November
2013 and used to derive organoid cell line MP015-Org33. The
patient’s disease was kept in check for nearly 2 more years
through a series of chemotherapeutic regimens, but following
progression, he was enrolled in a cell therapy protocol approved
by the M.D. Anderson Cancer Center Clinical Trials Institutional
Review Board to receive autologous, expanded tumor-antigen-
specific CTLs. Immunopeptidome analysis performed on the
expanded organoid cell line MP015-Org in May 2015 led to the
identification of 6 HLA class I-bound peptides (4 derived from
MUC16 and 1 each from ZNF717 and VGLL1) that met our
criteria as safe, targetable TAAs (Fig. 1b and Supplementary
Table 1). Custom clinical-grade tetramers were available for 3 of
the 6 potential targets: two HLA-B*3502-restricted MUC16
peptides and the single HLA-A*0101-restricted VGLL1 peptide.
Following leukapheresis, patient MP015 PBMCs were stimu-
lated twice with individual peptide-pulsed DCs in the presence
of IL-21, followed by tetramer-based sorting of antigen-specific
CD8+ T cells (Fig. 4a). Although MUC16-specific CTLs failed to
expand from patient PBMCs, VGLL1 CTLs expanded success-
fully, with VGLL1 tetramer-positive T cells comprising 3.4% of
CD8+ cells after 2 weeks of DC-peptide stimulation (Fig. 4b).
Cell sorting followed by employment of the rapid expansion
protocol (REP) was repeated twice, resulting in nearly 20 billion
expanded CTLs, of which >90% were VGLL1 tetramer-positive
and demonstrated restricted Vβ usage (Fig. 4b and c). Functional
VGLL1-specific CTLs were also successfully expanded from 2 of 2
healthy HLA-A*0101-positive blood donors, demonstrating the
general immunogenicity of the LSELETPGKY peptide (Supple-
mentary Fig. 16).
Expanded CTLs from patient MP015 and Healthy Donor #1
were tested functionally using standard 51Cr release assays. Mel888
melanoma cells (VGLL1-negative, HLA-A*0101-positive) pulsed
with titrated amounts of VGLL1 peptide elicited recognition and
killing at peptide concentrations as low as 10 nM, indicating
relatively high affinity for cognate peptide (Fig. 4d and
Supplementary Fig. 16). Importantly, expanded patient-derived
CTLs also showed robust recognition of the autologous organoid
cell line MP015-Org from which the VGLL1 peptide was originally
detected by MS (Fig. 5a). In October 2015 following a pre-
treatment regimen of Cytoxan, patient MP015 was infused with
19.6 billion autologous, expanded VGLL1-specific CTLs, subse-
quently receiving interleukin-2 and pembrolizumab. Although the
patient experienced a transient fever (a frequent side effect of T-
cell-infusion-induced cytokine release), they experienced no
adverse events indicating potential CTL-mediated toxicities.
Unfortunately, scans in late November 2015 showed rapid disease
progression manifested as an interval increase in lung lesions and
pleural-based metastatic disease33. Surprisingly, a biopsy of a
pleural-based nodule taken at this time revealed a poorly
differentiated neuroendocrine tumor. DNA sequencing analysis
of serial liquid biopsies collected over the previous 18 months
provided evidence of an extremely rapid evolution of patient
MP015’s cancer due to numerous progressive genetic amplifica-
tions, deletions, re-arrangements, and epigenetic changes. RNAseq
analysis of lung metastases also demonstrated that a dramatic
reduction in VGLL1 transcript expression (35.1 TPM to 1.6 TPM)
had occurred between November 2013 and December 2015,
providing a potential explanation for the lack of clinical response
to ETC therapy (Supplementary Fig. 17). Patient MP015 expired in
January 2016 due to extensive complications deriving from the
progression of their lung metastases33.
VGLL1-specific CTLs show cytotoxicity against PDAC tumor
lines. Although patient MP015 did not experience clinical benefit
from adoptive transfer of their own VGLL1-specific CTLs, the
robust antitumor activity demonstrated by these T cells in vitro
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Fig. 4 Generation of VGLL1 antigen-specific CTLs from peripheral blood of patient MP015. a Schematic outlining the experimental procedure for
generating VGLL1-specific CD8+ T cells from human donor PBMCs. b PBMCs isolated from PDAC patient MP015 by leukapheresis were stimulated with
autologous LSELETPGKY peptide-pulsed dendritic cells (DCs). After two stimulations, CD8+ and VGLL1 tetramer-positive cells were sorted and expanded
using a standard rapid expansion protocol (REP). VGLL1-specific T cells were re-sorted and expanded a second time due to low numbers of antigen-specific
cells following the first REP. The second REP yielded 19.6 × 109 VGLL1-specific CTLs, which patient MP015 safely received as an infusion under a
personalized ETC therapy Compassionate IND protocol. c T-cell receptor (TCR) repertoire analysis of expanded VGLL1-specific CTLs was performed using
Vβ antibodies corresponding to 24 different specificities. d VGLL1-specific T cells expanded from patient MP015 were tested for functionality in a standard
51Cr release assay to assess specific lysis of Mel888 melanoma cells (VGLL1-negative HLA-A*0101-positive) pulsed with titrated amounts of LSELETPGKY
peptide at a 5:1 effector-to-target (E:T) ratio. Data are presented as mean values+/− SD over three independent experiments.
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led us to explore whether they may have therapeutic potential for
other PDAC patients. HLA-A*0101 was expressed by ~30% of
our PDAC patient cohort, and RNAseq analysis of TCGA and
MDACC PDAC surgical specimens and PDXs showed that
43.2–62.5% of patients express VGLL1 transcript at a level >5
TPM. From these data, it is estimated that 12–15% of PDAC
patients present the LSELETPGKY peptide target in the context
of HLA-A*0101 and therefore could potentially benefit from
CTLs targeting VGLL1.
To determine if VGLL1 CTLs derived from patient MP015
could recognize allogeneic PDAC tumors, we tested a panel of
HLA-A*0101-expressing PDAC tumor cell lines as targets for
killing using a 51Cr release assay. Western blot analysis was used
to confirm VGLL1 protein expression, and flow cytometry
confirmed surface expression of HLA-A*0101 in cell lines
(Supplementary Fig. 18). While control cell line WM793
(VGLL1-negative, HLA-A*0101-positive) was not recognized,
VGLL1-specific CTLs recognized autologous MP015-Org cells
and 4 out of 4 allogenic PDAC lines tested, including inducing
robust killing of PANC10.05, CAPAN-1, and BXPC3 (Fig. 5a, b).
The PDAC organoid cells derived from patient MP081 were also
lysed by VGLL1 CTLs but with reduced efficiency, likely due to
an outgrowth of VGLL1-negative cells within the culture. HLA
class I specificity was demonstrated by co-incubation with the
pan-MHC class I antibody W6/32, which resulted in blockade of
PANC10.05 recognition and lysis (Supplementary Fig. 19).
Collectively, these results provide evidence that the LSE-
LETPGKY peptide constitutes a shared PDAC tumor antigen
that can be effectively targeted with VGLL1-specific CTLs.
VGLL1 CTLs show activity against multiple cancer cell lines.
TCGA RNAseq data analysis indicated that VGLL1 is expressed
by several additional cancer types (16 of 34 total), most notably in
75–80% of patients with bladder, ovarian, and basal-type breast
cancers, and 15–20% of patients with lung and gastric cancers
(Fig. 3b). We therefore set out to determine whether cell lines
derived from these cancer types could be targets for VGLL1-
specific CTLs (Fig. 6a). Western blot analysis of a panel of
ovarian, basal-type breast, bladder, gastric, and lung cancer cell
lines showed high VGLL1 expression in 11 of 13 lines analyzed
(Fig. 6b). Of the 8 cell lines that naturally expressed HLA-
A*0101, VGLL1 CTLs killed 2 of 3 ovarian lines, 2 of 3 breast
lines, and 1 of 1 bladder cancer lines (Fig. 6a). Interferon-gamma
treatment of tumor cell lines did not significantly alter recogni-
tion and killing by VGLL1 CTLs (Supplementary Fig. 20). Five
additional HLA-A*0101-negative cell lines (2 gastric, 2 bladder,
and 1 lung line) were transduced to express HLA-A*0101 prior to
testing them as targets for VGLL1 CTLs. As shown in Fig. 6a, all
five HLA-A*0101-transduced cell lines were rendered susceptible
to killing by VGLL1 CTLs, indicating presentation of the LSE-
LETPGKY peptide from processed, endogenously-expressed
VGLL1 protein. Taken together, these results suggest that
VGLL1 CTLs have potential therapeutic value for at least five
additional cancer types besides PDAC.
In order to assess the safety of VGLL1 CTLs for potential
therapeutic use, we tested them against a panel of normal primary
cells most likely to elicit VGLL1-specific reactivity according to
the GTex normal tissue expression profile (Fig. 2a). Since bladder
demonstrated the highest normal tissue VGLL1 transcript
expression, we tested two different HLA-A*0101-positive pri-
mary bladder cell lines as targets for killing. As shown in Fig. 6c,
specific lysis was low, detectable in one bladder line but only at
the highest E:T ratio. Since the GTex database indicated that
VGLL1 transcript is also expressed at low levels in normal breast
and lung, we tested VGLL1-specific CTLs against HLA-A*0101-
expressing primary mammary and lung airway cells, along with
primary melanocytes as a negative control. Of this panel,
mammary cells elicited moderately high levels of killing by
VGLL1-specific CTLs, results that were consistent with VGLL1
protein levels as assessed by Western blot (Fig. 6d and
Supplementary Fig. 22). By contrast, lung airway epithelial cells
were not killed by VGLL1 CTLs, despite demonstrating ample
HLA-A*0101 surface expression (Supplementary Fig. 18). These
results provide evidence that VGLL1-specific T cells are unlikely
to recognize essential normal tissues; however, safety concerns
may be warranted due to the potential for reactivity against some
non-essential tissues, including bladder and mammary tissue.
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HLA-A*0101+ controls HLA-A*0101+ allogeneic PDAC lines
Fig. 5 VGLL1-specific CTLs recognize and kill multiple allogeneic pancreatic cancer cell lines. a Expanded VGLL1-specific CD8+ T cells from patient
MP015 were co-cultured with a panel of HLA-A*0101-positive PDAC tumor cell lines in a standard 51Cr release assay to measure cytotoxic activity at
different effector-to-target (E:T) cell ratios. WM793 melanoma cells (VGLL1-negative, HLA-A*0101-positive) were used as a negative control line. VGLL1
CTLs robustly killed the autologous organoid cell line MP015 from which the VGLL1 peptide was originally isolated, and also demonstrated cytotoxic
activity against four allogeneic, HLA-A*0101-expressing PDAC cell lines. Results show the means and standard deviations of six replicate samples, and data
is representative of 4 independent experiments. b Western blot analysis showing expression of VGLL1 protein in all five PDAC cell lines tested was
repeated three times with similar results.
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Discussion
The benefits of immunotherapy have been slow to translate to
PDAC patients, likely due to the relatively low mutational bur-
den, highly suppressive tumor microenvironment, and a lack of
known TAA targets for CTL therapies32,45. Oncogenic driver
mutations in KRAS represent particularly promising target epi-
topes due to their tumor specificity and high prevalence in PDAC,
colorectal cancer (CRC), and lung cancer. In an exciting recent
case study, CTLs expanded from TILs of a CRC patient specifi-
cally recognized an HLA-C*0802-restricted KRAS peptide con-
taining the G12D mutation; furthermore, these TILs were shown
to mediate an objective tumor regression of multiple lung
metastases in the patient following infusion26. While highly
promising, the low worldwide prevalence of HLA-C*0802 pre-
dicts that only ~1.5% of PDAC patients could benefit from tar-
geting this mutated epitope. TCRs recognizing mutated KRAS
epitopes restricted to HLA-A*1101 have also been reported;
although not yet tested in clinical trials, the relatively high pre-
valence of A*1101 predicts a significantly larger potential patient
population that would be centered largely in Asia46. The lack of
shared mutations beyond KRAS suggests that identification and
targeting of non-mutated TAAs may represent the most pro-
mising opportunity for advancing immunotherapies for PDAC.
Two well-studied TAAs for PDAC and ovarian cancer, MUC16,
and CEACAM5, illustrate the two principal challenges of tar-
geting non-mutated TAAs: difficulty in breaking T-cell tolerance
and, conversely, the potential for induction of on-target off-tumor
toxicities. Based on low overall normal tissue and relatively high
tumor expression, MUC16 appears to be an ideal TAA; however,
isolating high-affinity CTLs that recognize non-mutated MUC16
epitopes has proven elusive23,47. This lack of immunogenicity
may be attributed to tolerogenic attributes of MUC16: being
detectable at low levels in healthy patient serum, and also being a
very large protein (>25,000 AA) containing >50 extracellular
tandem repeat domains48. By contrast, CEACAM5 transcript is
highly expressed in tumors but also in normal colon and eso-
phagus (>300 TPM), leading to severe colitis in patients treated
with antigen-specific T cells30.
Employing an unbiased immunopeptidome analysis of tumor
specimens derived from 35 PDAC patients, VGLL1 was identified
as a putative shared TAA, ranked second only to MUC16 in
terms of tumor expression in comparison to essential normal
tissues. However, in contrast to MUC16 epitopes, the HLA-
A*0101-restricted VGLL1 peptide was considerably more
immunogenic, capable of eliciting antigen-specific CTLs from
multiple donors, including one PDAC patient. Such immuno-
genicity provides a significant advantage in the context of
developing endogenous T-cell (ETC) therapies for cancer
patients. HLA-A*0101 is expressed at a relatively high prevalence
(25–30%) in Western European and North American countries,
suggesting that these patient populations would be most likely to
benefit from targeting this epitope49. Expanded VGLL1-specific
CTLs not only recognized and killed a panel of allogenic PDAC
tumor lines, but also demonstrated reactivity against A*0101-
expressing tumor cells derived from five other cancer types.


















































































































































































































Effector cell-to-target cell ratio
E:T ratio





























































































































Fig. 6 VGLL1-specific T cells recognize and kill multiple tumor types, but have reduced recognition of primary tissue cell lines. a VGLL1-specific CD8+
T cells were co-cultured with 12 different HLA-A*0101-expressing tumor cell lines derived from ovarian, lung, breast, bladder, or gastric cancer in a
standard 51Cr release assay to measure cytotoxic activity at different effector-to-target (E:T) cell ratios. Five HLA-A*0101-negative cell lines (H1299,
HT1197, HT1376, GT-5, and MKN74) were lentivirally transduced to stably express HLA-A*0101; specific killing of the parental cell lines (gray lines) are
shown in comparison to HLA-A*0101-transduced counterparts (black lines). Data are presented as mean values from three independent experiments +/−
SD. b Western blot analysis showing VGLL1 protein expression in tumor cell lines derived from ovarian, lung, breast, bladder, or gastric cancers was
repeated three times with similar results. c VGLL1-specific CTLs were co-cultured with HLA-A*0101-expressing primary tissue cells derived from bladder,
breast, lung airway, or skin melanocytes in a standard 51Cr release assay to measure cytotoxic activity. Cytolysis assay results show the means and
standard deviations of six replicate samples, and data is representative of three independent experiments. d VGLL1 protein expression in primary cell lines
as assessed by Western blot analysis was repeated three times with similar results.
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potentially benefit a large number of Western cancer patients,
including over 20% of patients with ovarian, bladder, or basal-like
breast cancers, ~12% of patients with PDAC, and 5–8% of
patients with lung, stomach, cervical, uterine, or head and neck
cancers (Fig. 3).
Higher VGLL1 expression has been associated with shorter
patient survival in multiple cancer types, including triple-negative
breast and endometrial cancers41,50. However, its negative impact
on survival is most striking in PDAC (Fig. 2b, c), suggesting that
VGLL1 may play a role in driving tumor aggressiveness. VGLL1
is a co-transcriptional activator and a marker of proliferating
cytotrophoblasts during early human placental development
where it is co-expressed with the transcription factor TEAD443,51.
VGLL1 is thought to play a role in the Hippo signaling pathway,
which controls organ size and is co-opted in multiple cancers to
drive tumor progression52,53. Two well-characterized oncogenes,
YAP and TAZ, function as co-transcriptional activators of the
Hippo signaling pathway, and in cancers they also bind to TEAD
proteins, leading to the upregulation of several cancer-promoting
genes39,54,55. VGLL1 has been shown to interact with TEAD4 in a
manner similar to that of YAP/TAZ, resulting in upregulation of
the proliferation-promoting gene IGFBP5 and facilitating
anchorage-independent cell proliferation51. These studies suggest
that VGLL1 may promote cancer progression directly, which
would increase its potential value as a therapeutic target.
Although the VGLL1 transcript loss observed in patient MP015
could argue against a role as an essential driver gene, the degree of
tumor evolution documented in this patient’s cancer progression
was exceptionally high33. Nonetheless, it does underscore the
importance of antigen drift and the necessity of minimizing the
time between personalized TAA identification and administration
of TAA-specific CTL therapies. Further studies will be required to
delineate the precise role of VGLL1 as a potential driver of
tumorigenesis.
The discovery of VGLL1 prompted us to search for other
putative CPAs that demonstrated overexpression in placenta and
tumors, and thus may constitute potential TAA targets. This
search uncovered placenta-specific 1 (PLAC1), initially identified
as a target of autologous humoral immunity in gastric cancer and
hepatocellular carcinoma patients, and the first CPA reported to
represent a class of TAAs distinct from CTAs and oncofetal
antigens56,57. A TCR recognizing an HLA-A*0201-restricted
peptide derived from PLAC1 was recently isolated and shown to
possess antitumor activity against human breast cancer cells in
pre-clinical models, but have not yet been tested in clinical
trials58. As shown in Fig. 3, PLAC1 shows low normal tissue
expression, but also demonstrates low overall prevalence in can-
cer. By contrast, insulin-like growth factor 2 mRNA binding
protein 3 (IGF2BP3) was also identified as a promising CPA in
our screen, showing relatively high prevalence of expression in
~15 different cancer types, including glioblastoma, uterine, tes-
ticular, and lung cancers (Fig. 3). The high level of IGF2BP3
expression in normal testis, transformed lymphocytes and
transformed fibroblasts suggest that this protein may also play a
role in driving cancer progression, consistent with its identifica-
tion as a poor prognostic factor59,60. Unfortunately,
IGF2BP3 shows a significant degree of amino acid identity with
IGF2BP2, which is expressed at elevated levels in several essential
normal tissues, thus limiting the number of safely targetable
epitopes. Of the 10 putative CPAs identified, matrix metallo-
peptidase 11 (MMP11) showed the most striking expression and
prevalence, being expressed at high transcript levels in 25 dif-
ferent cancer types (Fig. 3). However, in addition to normal
placenta, MMP11 is also expressed at relatively high levels in
uterus, cervix, and ovary, suggesting that CTL-based targeting of
MMP11 epitopes may result in reproductive toxicities for women.
In terms of safety profile, cancer prevalence, and immuno-
genicity, VGLL1 compares favorably with other known TAA
targets. Moreover, one PDAC patient treated with autologous,
high-affinity VGLL1-specific CTLs experienced no apparent
autoimmune toxicities, providing evidence that VGLL1 can be
safely targeted in vivo. However, in vitro testing did demonstrate
reactivity against cultured HLA-A*0101 primary mammary and
bladder cells, suggesting that safety considerations should be
taken into account when targeting CPAs. Immediate clinical
applications of these findings include a planned clinical trial to
treat HLA-A*0101+/VGLL1+ PDAC patients with VGLL1-
specific ETC therapy, with future cohorts to potentially include
bladder, ovarian, and/or breast cancer patients. Although an
important limitation of the current study is the validation of
VGLL1-specific CTL reactivity in only a single PDAC patient
(MP015), VGLL1-specific TCRs derived from this patient have
been cloned and are currently undergoing validation for future
potential clinical applications, including TCR-T-cell therapies.
MS-based identification of additional VGLL1 epitopes restricted
to other HLA allotypes is also ongoing, with the promise of
expanding the number of treatment-eligible cancer patients61.
Although single antigen-based targeting can demonstrate limited
clinical utility due to selection of antigen-loss variants, tumor
debulking and subsequent epitope spreading constitute important
aspects of immunotherapeutic success, processes that may be
further augmented when combined with other modalities such as
checkpoint blockade15,16. Collectively, our study shows that
VGLL1 is a promising TAA target that can be used in immune-
based therapies to address a serious unmet need in patients with
PDAC and multiple other cancer types.
Methods
Cell lines. Human cancer cell lines demonstrating VGLL1 mRNA expression were
identified using the Cancer Cell Line Encyclopedia (CCLE) microarray-based gene
expression analysis. HLA-A*0101-expressing cancer cell lines PANC10.05,
CAPAN-1 OAW28, HT1197, HT1376, BXPC3, UBCL-1, and primary cell lines
were obtained from commercial sources (ATCC and Sigma-Aldrich). The patient-
derived organoid cell line MP015-Org (hMIA2D) was generated by the Tuveson
lab at Cold Spring Harbor Labs33. The patient-derived organoid cell line MP081-
Org was generated by the Maitra lab from tumor tissue derived from a wedge
biopsy. The gastric cancer cell lines GT-5 and MKN74 were a kind gift from Dr.
Lee Ellis. WM793, MKN74, PANC1005, GT-5, and OAW28 cells were cultured in
RPMI 1640 medium (GIBCO), containing 10% fetal bovine serum, 1%
penicillin–streptomycin (Pen-Strep) (Cellgrow), and 1%
Insulin–Transferrin–Seleum-A (GIBCO). BT20 and bladder cell lines were cultured
in equal parts DMEM F12K and MEM Alpha, with FBS, Pen-Strep, and 1% sodium
pyruvate (GIBCO). All other cell lines were cultured in RPMI 1640, FBS, and 1%
Pen-Strep, with the addition of HEPES (GIBCO) and Glutamax (GIBCO).
Lentiviral transductions. Some HLA-A*0101-negative tumor cell lines that
naturally expressed VGLL1 protein were transduced with a lentiviral gene transfer
vector to express HLA-A*0101 driven by the human PGK promoter62. Ectopic cell
surface expression of A*0101 was assessed by staining with anti-human HLA-A1-
biotin and streptavidin-FITC (US Biological) and measuring fluorescence using a
FACScanto II flow cytometer (BD Biosciences). Transduced tumor cells expressing
physiological levels of surface HLA-A*0101 by fluorescence compared to tumor
cells naturally expressing A*0101 were isolated by cell sorting using a FACSAria
Fusion (BD Biosciences), expanded, and used in subsequent experiments.
VGLL1 protein expression. VGLL1 protein expression was confirmed in all cell
lines by western blot analysis. Cell lysates from tumor and primary cell lines were
prepared and protein content normalized using the BCA method (Thermo-Fisher).
Using standard Western blot techniques, cell lysates were run by polyacrylamide
gel electrophoresis, transferred, and membranes probed with VGLL1-specific rabbit
polyclonal antibody (TA322329, OriGene). VGLL1 protein was visualized using an
enzyme-linked anti-rabbit mAb with the Scientific Pierce Fast Western Blot Kit,
according to the manufacturer’s instructions. Full scan blots can be found in
Supplementary Fig. 22.
Mass spectrometry-based peptide identification. Patient-derived laparoscopic
wedge biopsies, xenografts (PDX), or cell lines were lysed using Triton X-100 and
cell lysates incubated overnight at 4 °C with 50 μg of pan-HLA-ABC specific mAb
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W6/32 for every 10 mg of protein. Protein A/G Ultralink resin beads were used to
immunoprecipitate HLA class I molecules and HLA-bound peptides were then
eluted with 0.1 M acetic acid. HLA-A,B,C isolation was confirmed by Western blot
analysis, then HLA-positive elutes were analyzed by tandem mass spectrometry
(MS/MS). HLA class I protein recovery was semi-quantitatively assessed by rating
Western blot band intensity on a scale from 0 (not detectable) to 4 (highest
intensity). Molecular weight filters were employed if tumor specimens were of
sufficient size (>250 mg), but sample losses precluded this technique with smaller
specimens. Eluted peptides were analyzed by high-sensitivity LC-MS/MS using a
Nano-Cap LC system (Dionex Ultimate 3000 RSLC-Nano) interfaced to a tribrid
mass spectrometer (Thermo Scientific Fusion) using ESI. Chromatography was
performed using 0.1% formic acid in water as A solvent, 0.1% formic acid in
acetonitrile as B solvent. Gradient initial conditions, 2% B for 5 min, gradient to
35% B over 40 min, 1 min ramp to 80% B, hold for 5 min, return to 2% B for re-
equilibration. A 15 cm Column was packed with Phenomenex Kinetex 2.6 micron
XB-C18, 100-angstrom particles. MS conditions electrospray source, full MS1
range was 265–1500m/z at 240,000 resolution AGC settings, target ions 5-e5,
maximum time 100 ms, for doubly charged precursors the selection range was
limited to 400–750m/z, for triply charged precursors the selection range was
limited to 270–500m/z. MS/MS was performed in the linear ion trap, AGC set-
tings, target ions 4-e5, maximum time, 300 ms, isolation window 0.7 da, cycle time
between master scans, 1.5 s, number of precursors, automatic, dynamic exclusion
time 20 s. To analyze the acquired MS/MS spectra, the Mascot algorithm was
utilized to search the spectra against the SwissProt complete human protein
database (updated 9/2018), which provided potential matches to conventionally
annotated peptides. In selected cases, targeted-MS/MS analysis was performed to
confirm TAA peptide identity. For these analyses, retention-time windows for 13C/
15N isotope-labeled synthetic peptide standards were pre-determined by MS ana-
lysis of the synthetic peptides, then targeted methods for searching TAA peptides
were constructed using mass windows of 3 Da around each m/z. Peptide spectra are
shown with y+ fragment ions color-coded blue, b+ fragment ions red, and non-
matching fragments in gray. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identifier PXD018302 (https://www.ebi.ac.uk/pride/).
Peptide selection and validation. Individual peptide matches underwent quality
assessment by reference to multiple orthogonal parameters, including Mascot Ion
score, MS1 measured differential to the calculated peptide mass (delta mass), and
predicted binding to the patient’s HLA allotypes as determined by high-resolution
genetic sequencing and the NetMHC and NetMHCpan algorithms34,35. Peptide
matches were analyzed by BLAST searches to identify all potential source genes,
which were then cross-referenced to RNAseq data derived from individual tumor
samples to provide further validation of peptide identity (validation requiring a
minimum source gene expression of 0.3 transcripts per million, TPM). Eluted TAA
peptides were screened for safety as potential CTL targets by applying sequential
RNA transcript expression filters to eliminate peptides most likely to elicit auto-
immune toxicities due to normal tissue expression (GTex Portal RNAseq data,
http://cancergenome.nih.gov/). Excluding testis and placenta, source gene tran-
script expression of 30 TPM maximum was allowed in non-essential tissues (listed
in Supplementary Table 2), 10 TPM in caution tissues, 3 TPM in hazard tissues,
and 1 TPM in highly essential danger tissues (such as heart and brain). Putative
TAA genes were also screened for expression and prevalence in different cancer
types through analysis of TCGA RNAseq data (http://cancergenome.nih.gov/). The
RNAseq TPM thresholds were chosen based on the following reasons: Two pub-
lished studies that have reported fatalities from adoptive transfer of engineered
antigen-specific TCR-T cells have shown that MAGEA3-specific T cells cross-
reacted with either a Titin-derived peptide in the heart (where GTex Titin
expression is ~60 TPM), causing cardiac arrest; or cross-reacted with a MAGEA12
peptide in the brain (where the GTex database showed MAGEA12 expression was
median ~0.3 TPM)37,63. We chose 1 TPM as the safety threshold for TAAs
expressed by the heart and brain, which were considered danger tissues; however, it
is possible that antigens expressed at levels lower than 1 TPM may be recognized
by T cells. Lung, liver, colon, stomach, and esophagus were considered as hazard
tissues since though they are clearly essential, T-cell therapies have not been shown
to lead to any fatal cross-reactivities. We therefore chose a threshold 3-fold higher
(3 TPM) as an acceptable level of expression for these tissues. We chose 10 TPM as
threshold for hematopoietic tissues and 30 TPM for non-essential tissues, since
targeting of these tissues with tumor-antigen-specific T cells would not be likely to
lead to fatalities, although we cannot rule out autoimmune toxicities, as we discuss
in the manuscript. In our experience attempting to derive and expand cytotoxic
T cells against multiple non-mutated peptides from donor peripheral blood, we
have found that it is highly challenging to generate T cells against genes with
expression >30 TPM in any normal tissue (likely due to deletional tolerance),
which determined the upper TPM limit.
Gene expression analysis and patient survival. Whole transcriptome sequencing
(RNAseq) analysis was performed on RNA derived from all PDAC tumor speci-
mens, xenografts, and organoid cell lines using the Illumina TruSeq Stranded Total
RNA kit with Ribo-Zero Gold with ~200 million paired-end reads for each tumor
RNA sample (Avera Institute for Human Genetics). Gene expression profiles of
VGLL1 and other cancer-placenta antigens were determined by compiling RNAseq
data derived from normal human primary tissues (GTex Portal) and tumor tissues
(TCGA). Kaplan–Meier curves were generated from survival data of TCGA cancer
patients when stratified by tumor VGLL1 transcript expression.
Isolation and expansion of VGLL1-specific CD8 T cells. Tumor-antigen-specific
CTLs were generated as previously described64–66. HLA-A*0101-positive patient-
or healthy donor-derived PBMCs were stimulated twice by autologous dendritic
cells (DCs) pulsed with the VGLL1231-240 peptide LSELETPGKY. Six days after the
second DC stimulation, cultured cells were stained with VGLL1231-240 peptide/
HLA-A*0101–PE-conjugated custom tetramer (1:150 dilution, Fred Hutchinson
Cancer Research Center), washed, and then stained with APC-conjugated CD8
antibody (1:25 dilution). Cells were washed and analyzed by flow cytometry
(LSRFortessa X-20 Analyzer). CD8 and tetramer double-positive cells were sorted
by ARIA II and the VGLL1-specific CD8 T cells were expanded using the Rapid
Expansion Protocol (REP) with PBMCs and EBV-immortalized lymphoblastoid B-
cell lines (LCL) feeder cells. The TCR-Vβ repertoire of expanded CD8 T cells was
assessed using the IOTest Beta Mark TCR-Vβ Repertoire kit. An example of the
CTL gating strategy can be found in Supplementary Fig. 21.
Cytotoxic T-cell assays. Antitumor killing by VGLL1-specific CD8+ T cells was
assessed using a standard chromium-51 (51Cr) release assay. Target cells were
labeled with 100 μL of 51Cr for 1 h, then washed and plated at 2000 target cells per
well in triplicate. VGLL1-specific CD8+ T cells were incubated with target cells at
various effector-to-target (E:T) cell ratios for four hours. After the incubation
period, supernatant was collected from the wells and 51Cr was measured with a
gamma radiation counter. The percentage of specific target cell lysis was calculated,
correcting for background 51Cr release and relative to a maximum 51Cr release as
measured by Triton X-100 lysed target cells.
Adoptive transfer of VGLL1-specific T cells. All clinical investigations were
conducted according to the Declaration of Helsinki principles. PDAC patient
MP015 presented with metastatic pancreatic cancer and underwent several lines of
conventional and experimental therapy over a 4-year period including FOLFIR-
INOX, Bevacizumab, GVAX vaccine, and Gemcitabine/Abraxane that ultimately
failed to control the disease. Since this patient was refractory to treatment and had
exhausted conventional therapeutic options, it was deemed appropriate to consent
and treat them under a Compassionate Use Investigational Drug (CIND) protocol
approved by the U.S. Food and Drug Administration (FDA) and the M.D.
Anderson Cancer Center clinical trials IRB committee33. The generation of
antigen-specific CTL was performed according to methods established in the Yee
Lab15, summarized briefly as follows: PBMCs were collected by leukapheresis and
all ensuing ex vivo manipulations were performed in the Cell Processing Facility at
UT MD Anderson Cancer Center. Donor PBMC was stimulated two times 7 days
apart, with autologous dendritic cells (DC) pulsed with the VGLL1 peptide in the
presence of IL-21 (30 ng ml−1). Previous studies have shown that exposure of
T cells to IL-21 during in vitro priming leads to the generation of a unique
population of central memory type CD8 T cells (TCM) characterized by high
surface expression of CD28 and CD127 (typically 40–90% CD28+CD127+) that
enables long-term in vivo persistence of transferred T cells16,66,67. On Day 2 of each
stimulation, IL-2 (12.5 IUml−1), IL-7 (5 ng ml−1), and IL-15 (1 ng ml−1) were
added to obtain sufficient frequencies (>1% by multimer staining) of VGLL1-
reactive CD8+ T cells which were then selected by clinical-grade multimer-guided
sorting (Nanosorter, Owl Biomedical) and expanded using the Rapid Expansion
Protocol to >1e10 cells. Under the protocol, the patient received very low-dose
cyclophosphamide (300 mgm−2 iv) conditioning on Day −2 and then an infusion
of 1.9e10 polyclonal, IL-21 primed antigen-specific CTLm−2, immediately fol-
lowed by a 2-week course of low-dose s.c. IL-2 and PD1 blockade (3 mg kg−1 every
2 weeks × 16 doses). Radiologic responses were evaluated according to the mWHO-
based irRC Criteria33. Although the patient was hospitalized for monitoring of
potential cell-infusion-associated adverse events (AEs), no serious AEs were
observed apart from expected transient (<24 h) culture-negative fevers (≥38.3 °C),
associated with CTL-induced cytokine release syndrome, and lymphopenia lasting
<10 days33.
Statistical analysis. Data analysis was performed using GraphPad Prism version
7.03. Normally distributed data were analyzed using parametric tests (ANOVA or
unpaired t test). Kaplan–Meier survival curves were analyzed by log-rank tests. Test
differences were considered statistically significant if P < 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw mass spectrometry data of peptides eluted from organoid lines MP015 and
MP081 have been deposited in the ProteomeXchange Consortium database via the
PRIDE partner repository under the dataset identifier PXD018302 (https://www.ebi.ac.
uk/pride/). Complete MS search results and lists of peptides eluted from PDAC patients
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19141-w
10 NATURE COMMUNICATIONS |         (2020) 11:5332 | https://doi.org/10.1038/s41467-020-19141-w | www.nature.com/naturecommunications
MP015 and MP081 are shown in Supplementary Data 1 and 2. The GTex Portal database
and TCGA data referenced during the study are available in public repositories from
websites http://www.gtexportal.org/home/ and http://cancergenome.nih.gov/. All other
data supporting the findings of this study are available within the article and its
supplementary information files, or from the corresponding authors upon reasonable
request. Correspondence to Cassian Yee (cyee@mdanderson.org) or Gregory Lizee
(glizee@mdanderson.org). Complete raw patient RNAseq data has been deposited in the
European Nucleotide Archive under the study accession number PRJEB40462 (https://
www.ebi.ac.uk/ena/browser/home). A reporting summary for this article is available as a
Supplementary Information file.
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